McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
N Engl J Med. 2010 Feb 11;362(6):513-20. doi: 10.1056/NEJMoa0906260.
The optimal fractionation schedule for whole-breast irradiation after breast-conserving surgery is unknown.
We conducted a study to determine whether a hypofractionated 3-week schedule of whole-breast irradiation is as effective as a 5-week schedule. Women with invasive breast cancer who had undergone breast-conserving surgery and in whom resection margins were clear and axillary lymph nodes were negative were randomly assigned to receive whole-breast irradiation either at a standard dose of 50.0 Gy in 25 fractions over a period of 35 days (the control group) or at a dose of 42.5 Gy in 16 fractions over a period of 22 days (the hypofractionated-radiation group).
The risk of local recurrence at 10 years was 6.7% among the 612 women assigned to standard irradiation as compared with 6.2% among the 622 women assigned to the hypofractionated regimen (absolute difference, 0.5 percentage points; 95% confidence interval [CI], -2.5 to 3.5). At 10 years, 71.3% of women in the control group as compared with 69.8% of the women in the hypofractionated-radiation group had a good or excellent cosmetic outcome (absolute difference, 1.5 percentage points; 95% CI, -6.9 to 9.8).
Ten years after treatment, accelerated, hypofractionated whole-breast irradiation was not inferior to standard radiation treatment in women who had undergone breast-conserving surgery for invasive breast cancer with clear surgical margins and negative axillary nodes. (ClinicalTrials.gov number, NCT00156052.)
保乳手术后全乳照射的最佳分割方案尚不清楚。
我们进行了一项研究,以确定 3 周的短程全乳放疗方案是否与 5 周的方案一样有效。接受保乳手术且切缘阴性、腋窝淋巴结阴性的浸润性乳腺癌女性患者被随机分配接受标准剂量 50.0 Gy/25 次/35 天(对照组)或低分割剂量 42.5 Gy/16 次/22 天(短程放疗组)的全乳放疗。
612 例接受标准放疗的女性中有 6.7%在 10 年内发生局部复发,而 622 例接受短程放疗的女性中有 6.2%(绝对差值,0.5 个百分点;95%置信区间 [CI],-2.5 至 3.5)。10 年后,对照组中 71.3%的女性与短程放疗组中 69.8%的女性美容效果良好或优秀(绝对差值,1.5 个百分点;95%CI,-6.9 至 9.8)。
在切缘阴性、腋窝淋巴结阴性的浸润性乳腺癌保乳手术后的女性中,10 年后,加速、短程全乳放疗并不逊于标准放疗。(临床试验.gov 编号,NCT00156052)。